L1 Capital Global Opportunities Master Fund, Ltd. 13D and 13G filings for Sunshine Biopharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 4:43 pm Purchase | 2024-12-31 | 13G | Sunshine Biopharma, Inc. SBFM | L1 Capital Global Opportunities Master Fund, Ltd. | 142,244 4.990% | 139,601 (+5282.21%) | Filing |
| 2024-02-23 4:03 pm Purchase | 2024-02-13 | 13G | Sunshine Biopharma, Inc. SBFM | L1 Capital Global Opportunities Master Fund, Ltd. | 2,643 5.300% | 2,643 (New Position) | Filing |